European Society of Cardiology (ESC) Congress 2018 Munich, Germany - August 25-29, 2018

被引：0
|
作者：
Puzzovio, S. [1 ]
机构：
[1] Clarivate Analyt, Barcelona, Spain
来源：
DRUGS OF THE FUTURE | 2018年 / 43卷 / 10期
关键词：
LCZ-696; Bempedoic acid; AH-04A; Evolocumab; Rivaroxaban; Canakinumab; BAY-1753011; C-53; Neladenoson bialanate; Selexipag; Tafamidis; Edoxaban; Resmetirom; Dabigatran etexilate;
D O I：
10.1358/dof.2018.043.10.2904957
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The ESC Congress 2018, in Munich, Germany, once again formed the 'world's largest and most influential scientific congress for cardiovascular professionals' from worldwide locations. Over 5 days of science and education, approximately 4,500 abstracts were presented, 500 expert sessions given and > 200 exhibiting companies attended, delivering 'cutting-edge programs essential for continuing medical education' for the 'biggest killer in Europe'. The ESC Congress Spotlight for 2018 was valvular heart disease, a disease that is characterized by damage to or a defect in one of the four heart valves.
引用
下载
收藏
页码：777 / 782
页数：6
相关论文
共 50 条
12345